707 related articles for article (PubMed ID: 32212849)
1. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
Mason RP; Libby P; Bhatt DL
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1135-1147. PubMed ID: 32212849
[TBL] [Abstract][Full Text] [Related]
2. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
3. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
Borow KM; Nelson JR; Mason RP
Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
Fialkow J
Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
[TBL] [Abstract][Full Text] [Related]
5. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Preston Mason R
Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
[TBL] [Abstract][Full Text] [Related]
6. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
7. The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future.
Perez-Martinez P; Katsiki N; Mikhailidis DP
Angiology; 2020 Jan; 71(1):10-16. PubMed ID: 30966756
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
Oscarsson J; Hurt-Camejo E
Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
[TBL] [Abstract][Full Text] [Related]
9. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.
Zambon A; Pirillo A; Zambon S; Norata GD; Catapano AL
Curr Atheroscler Rep; 2020 Oct; 22(12):74. PubMed ID: 33009961
[TBL] [Abstract][Full Text] [Related]
10. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids.
Kris-Etherton PM; Richter CK; Bowen KJ; Skulas-Ray AC; Jackson KH; Petersen KS; Harris WS
Methodist Debakey Cardiovasc J; 2019; 15(3):171-178. PubMed ID: 31687095
[TBL] [Abstract][Full Text] [Related]
11. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
12. Understanding why REDUCE-IT was positive - Mechanistic overview of eicosapentaenoic acid.
Harris WS
Prog Cardiovasc Dis; 2019; 62(5):401-405. PubMed ID: 31666183
[TBL] [Abstract][Full Text] [Related]
13. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
Nelson JR; Wani O; May HT; Budoff M
Vascul Pharmacol; 2017 Apr; 91():1-9. PubMed ID: 28263852
[TBL] [Abstract][Full Text] [Related]
14. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
Shapiro MD; Fazio S
Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.
Jia X; Koh S; Al Rifai M; Blumenthal RS; Virani SS
Vasc Health Risk Manag; 2020; 16():1-10. PubMed ID: 32021223
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
[TBL] [Abstract][Full Text] [Related]
17. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
18. Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia.
Patel AA; Budoff MJ
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):145-9. PubMed ID: 26825470
[TBL] [Abstract][Full Text] [Related]
19. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
20. Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial.
Asztalos IB; Gleason JA; Sever S; Gedik R; Asztalos BF; Horvath KV; Dansinger ML; Lamon-Fava S; Schaefer EJ
Metabolism; 2016 Nov; 65(11):1636-1645. PubMed ID: 27733252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
